Evidence map›Paper›PMID 32774680›Full record

ArticleOxidative medicine and cellular longevity2020

Role of Nrf2 in Lipopolysaccharide-Induced Acute Kidney Injury: Protection by Human Umbilical Cord Blood Mononuclear Cells.

Li-Xin Feng, Fei Zhao, Qian Liu, Jin-Cheng Peng, Xiang-Jie Duan, Ping Yan, Xi Wu, Hong-Shen Wang, Yin-Hao Deng, Shao-Bin Duan

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Mechanisms of PMInternational journal of molecular sciences · 2024
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Li-Xin FengDepartment of Nephrology, The Second Xiangya Hospital, Central South University; Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan 410011, China.
Fei ZhaoDepartment of Nephrology, The Second Xiangya Hospital, Central South University; Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan 410011, China.
Qian LiuDepartment of Nephrology, The Second Xiangya Hospital, Central South University; Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan 410011, China.
Jin-Cheng PengDepartment of Nephrology, The Second Xiangya Hospital, Central South University; Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan 410011, China.
Xiang-Jie DuanDepartment of Nephrology, The Second Xiangya Hospital, Central South University; Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan 410011, China.
Ping YanDepartment of Nephrology, The Second Xiangya Hospital, Central South University; Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan 410011, China.
Xi WuDepartment of Nephrology, The Second Xiangya Hospital, Central South University; Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan 410011, China.
Hong-Shen WangDepartment of Nephrology, The Second Xiangya Hospital, Central South University; Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan 410011, China.
Yin-Hao DengDepartment of Nephrology, The Second Xiangya Hospital, Central South University; Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan 410011, China.
Shao-Bin DuanDepartment of Nephrology, The Second Xiangya Hospital, Central South University; Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan 410011, China.ORCID https://orcid.org/0000-0002-4677-5704
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute kidney injury (AKI) is one of the common complications of sepsis. Heretofore, there is no effective treatment for septic AKI. Recent studies have revealed that besides treating hematological malignancies, human umbilical cord blood mononuclear cells (hUCBMNCs) show good therapeutic effects on other diseases. But whether hUCBMNCs can protect against septic AKI and its underlying mechanism are unknown.

methodsThe rat model of lipopolysaccharide- (LPS-) induced AKI was developed, and the injection of hUCBMNCs was executed to prevent and treat AKI. ML385, a specific nuclear factor E2-related factor 2 (Nrf2) inhibitor, was used to silence Nrf2. The cell experiments were conducted to elaborate the protective mechanism of Nrf2 pathway.

resultsAn effective model of LPS-induced AKI was established. Compared to the rats only with LPS injection, the levels of inflammation, reactive oxygen species (ROS), and apoptosis in renal tissues after hUCBMNC injection were markedly attenuated. Pathological examination also indicated significant remission of renal tissue injury in the LPS+MNCs group, compared to rats in the LPS group. Transmission electron microscopy (TEM) showed that the damage of the mitochondria in the LPS+MNCs group was lighter than that in the LPS group. Noteworthily, the renal Nrf2/HO-1 pathway was activated and autophagy was enhanced after hUCBMNC injection. ML385 could partly reverse the renoprotective effect of hUCBMNCs, which could demonstrate that Nrf2 participated in the protection of hUCBMNCs. Cell experiments showed that increasing the expression level of Nrf2 could alleviate LPS-induced cell injury by increasing the autophagy level and decreasing the injury of the mitochondria in HK-2 cells.

conclusionAll results suggest that hUCBMNCs can protect against LPS-induced AKI via the Nrf2 pathway. Activating Nrf2 can upregulate autophagy to protect LPS-induced cell injury.

Indexed as

Acute Kidney InjuryAnimalsFetal BloodHumansLeukocytes, MononuclearLipopolysaccharidesMaleNF-E2-Related Factor 2RatsRats, Sprague-DawleyLipopolysaccharidesNF-E2-Related Factor 2

Identifiers

PMID32774680
PMCPMC7407026
OpenAlexW3045500226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.